Skip to main content

Galapagos Raises $430K through Warrants Exercise

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Belgian drug discovery company Galapagos today announced it increased its shares capital by about €350,000 ($430,000) through the exercise of employee warrants.

The firm issued 40,160 new ordinary shares today for an average of €8.71 per share. Following today's capital increase, the company has a share capital of more than €129 million with a total of almost 24 million shares outstanding.

Galapagos uses warrant plans to "incentivize personnel and management and have them share in the success of the company," it said in a statement. The company added that no board members or executive members exercised warrants in the round.

The company also announced that it has received a transparency notification indicating that an individual identified as A. Strating, as well as companies TWE Beheer, TWE Investment, and Gestion Deelnemingen V combined hold nearly 1.3 million shares, or 5.25 percent of Galapagos' shares.

Gestion previously notified Galapagos that it held almost 1.2 million shares, or 5.02 percent of the company's shares.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.